Wilbanks Smith & Thomas Asset Management LLC held its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,815 shares of the pharmaceutical company’s stock at the close of the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $363,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Teachers Advisors LLC increased its stake in Vertex Pharmaceuticals by 48.6% in the 1st quarter. Teachers Advisors LLC now owns 510,373 shares of the pharmaceutical company’s stock valued at $55,809,000 after buying an additional 166,998 shares during the last quarter. Dynamic Capital Management Ltd increased its stake in Vertex Pharmaceuticals by 53.8% in the 1st quarter. Dynamic Capital Management Ltd now owns 39,614 shares of the pharmaceutical company’s stock valued at $4,332,000 after buying an additional 13,853 shares during the last quarter. Delta Lloyd Asset Management N.V. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $3,285,000. NorthCoast Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $782,000. Finally, Prudential Financial Inc. increased its stake in Vertex Pharmaceuticals by 12.8% in the 2nd quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock valued at $57,312,000 after buying an additional 50,350 shares during the last quarter. Hedge funds and other institutional investors own 92.85% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down 1.49% during mid-day trading on Wednesday, reaching $152.21. 360,993 shares of the company’s stock were exchanged. The company has a 50-day moving average of $154.33 and a 200-day moving average of $135.12. The stock has a market cap of $38.38 billion, a price-to-earnings ratio of 147.78 and a beta of 1.73. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.33. The firm had revenue of $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company’s revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the company earned $0.24 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current year.

In other news, CMO Jeffrey Chodakewitz sold 573 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $129.85, for a total value of $74,404.05. Following the completion of the transaction, the chief marketing officer now owns 123,084 shares in the company, valued at $15,982,457.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul M. Silva sold 43,443 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $161.07, for a total transaction of $6,997,364.01. Following the completion of the transaction, the senior vice president now owns 26,516 shares of the company’s stock, valued at approximately $4,270,932.12. The disclosure for this sale can be found here. Insiders sold 518,357 shares of company stock valued at $83,154,633 in the last quarter. Corporate insiders own 1.80% of the company’s stock.

Several equities research analysts have issued reports on the stock. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 1st. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. DA Davidson assumed coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Finally, BTIG Research assumed coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $167.04.

WARNING: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/wilbanks-smith-thomas-asset-management-llc-has-363000-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.